GRENADE AT4 - 120 caps
Grenade AT4 Anabolic Devastation by Grenade has been formulated to increase testosterone in a natural manner, providing optimal hormonal support to the organism to create an environment propitious for:
- Increase physical performance
- Stimulate muscle congestion
- Accelerate recovery processes
- Develop muscle mass to the max
As we know, to increase our strength and muscle mass to the utmost, we must not only train arduously and supplement with mass gainers and proteins. We must also achieve the optimal hormonal balance.
Testosterone is the most anabolic hormone there is. It determines the amount of muscle that can be built. Testosterone also helps to keep men energetic and active to take training to another level. It leads to a greater feeling of confidence and self-esteem and also accelerates muscle recovery.
Grenade ® AT4 contains the latest proven ingredients to stimulate the synthesis of testosterone, favouring muscle growth, accelerating recovery and stimulating muscle pumps. Amongst its ingredients are D-Aspartic Calcium Chelate, Fenurex™ (as Trigonella Foenum Graecum), Passiflora Caerulea, boric acid and a mega-dose of vitamin D3.
Grenade AT4 Anabolic Devastation by Grenade has been developed with quick dispersion technology to ensure effective and high quality delivery into the digestive tract and for each one of the active principles to be completely absorbed. It is a totally safe product which complies with standards established by the competent British and European authorities in order to classify it as a totally legal food supplement. Grenate AT4 is designed to provide hormonal support only for men, the ingredients havent been tested on women and may produce unwanted side effects in women.
|per servingDaily dose|
|Serving size: 3 capsules|
|Daily dose: 6 capsules|
|Servings per container: 40|
|Amount per serving||NRV*|
|Vitamin D3 (Cholecalciferol)||12.5ug||250%|
|D-Aspartic Acid (DAA) calcium chelate||1500mg||++|
|Boron (boric acid)||4.75mg||++|
|NRVs (Nutrient Reference Values) established in Regulation (EU) 1169/2011 of 25 October 2011. †† NRVs are not established on this occasion.|